InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: ash111 post# 40449

Friday, 10/20/2017 11:21:07 AM

Friday, October 20, 2017 11:21:07 AM

Post# of 48316
They have also said they will execute the ATM (obviously on data releases to take advantage of price spikes and reduce the dilution). The ATM is for roughly $8 mil so we are good until data release mid 2018. Good results will have Merck 100% stepping in with financial support.....something similar to KALV (Kalvista pharma) recent deal. Just for comparison, KALV market cap spiked to 150 mil and is now around 100 mil market cap after their deal with Merck. Since Merck went big on Cubist for 8 billion, their more recent strategy has been to go after or support small cap biotech companies.